medigraphic.com
Colegio de Medicina Interna de México.

2012, Number 5

<< Back Next >>

Med Int Mex 2012; 28 (5)

Endocrine Paraneoplastic Syndromes. Literature Review

López HMA

Language: Spanish
References: 52
Page: 454-460
PDF size: 204.82 Kb.


ABSTRACT

The endocrine or humoral paraneoplastic síndromes can be defined as clinical entities, caused by a distance effect of a tumor, independiently of the local effect of its metastases, thath ocurrs mediated by the ectopical production of hormonal peptides o their precursors, citokines and rarely by tiroid hormone or D vitamin. The endocrine paraneoplastic syndromes, are important clinic entities associated to many kind of tumors. The importance of the knowledge of this syndromes is the chance to make a early diagnostic of a previously undiagnosed oncologic entity, avoid the diagnostic mistake induced by this syndromes that can be the predominant clinical scenario, or can be useful for monitoring the evolution and response to the treatment of the neoplasm that originate them.vIn this review are considerated the next paraneoplastic syndromes: the inappropriate secretion of the antidiuretic hormone, the malignancy´s hypercalcemia, hypoglycaemia, Cushing syndrome and acromegaly.


REFERENCES

  1. Oppenheim H. Über Hirnsymptome bei Carcinomatose ohne nachweisbare Veränderungen im Gehirn. Charité-Annalen (Berlin) 1888;(13):335-344.

  2. Guichard A, Vignon G. La Polyradiculonéurite cancéreuse métastatique. J Med Lyon 1949;30:197-207.

  3. Schartz WD, Bennet W, Curelop S, Bartter F. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:529-542.

  4. Pequeux C, Breton C, Hendrick JC, et al. Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/ paracrine signaling. Cancer Research 2002;62:4623- 4629.

  5. DeLellis RA, Xia L. Paraneoplastic endocrine syndromes: a review. Endocrine Pathology 2003;14:303-317.

  6. Radulescu D, Bunea D, Pripon S, et al. Severe paraneoplastic hyponatremia and hypoosmolality in a patient with smallcell lung carcinoma: syndrome of inappropriate antidiuretic hormone secretion versus atrial natriuretic peptide or both? Clinical Lung Cancer 2007;8(6):392-395.

  7. Lumachi F, Brunello A, Roma A, Basso U. Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 2008;15:415-421.

  8. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990;112:499-504.

  9. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373-379.

  10. Stewart AF, Broadus AE. Malignancyassociated hypercalcemia. In: DeGroot L, Jameson LJ, eds. Endocrinology. 5th ed. Philadelphia: Saunders (in press).

  11. Horwitz MJ, Stewart AF. Humoral hypercalcemia of malignancy. In: Favus MF, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington: American Society for Bone and Mineral Research, 2003;246-250.

  12. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664.

  13. Clines GA, Guise TA. Hypercalcemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington: American Society for Bone and Mineral Research 2003:251-256.

  14. Godsall JW, Burtis WJ, Insogna KL, Broadus AE, Stewart AF. Nephrogenous cyclic AMP, adenylate cyclase-stimulating activity, and the humoral hypercalcemia of malignancy. Recent Prog Horm Res 1986;42:705-750.

  15. Jara A, Lee E, Stauber D, Moatamed F, Felsenfeld AJ, Kleeman CR. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH. Kidney Int 1999;55:1434- 1443.

  16. Lentz RD, Brown DM, Kjellstrand CM. Treatment of severe hypophosphatemia. Ann Intern Med 1978;89:941-944.

  17. Goldsmith RS, Ingbar SH. Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med 1966;274:1-7.

  18. Steward AF. Hypercalcemia Associated with Cancer. N Engl J Med 2005;352:373-379.

  19. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.

  20. Major P, Lortholary A, Hon J, et al. oledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized,controlled clinical trials. J Clin Oncol 2001;19:558-567.

  21. Pecherstorfer M, Steinhauer EU, RizzoliR, Wetterwald M, Bergstrom B. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003;11:539-547.

  22. Cheer SM, Noble S. Zoledronic acid. Drugs 2001;61:799-805.

  23. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95: 297-304.

  24. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-290.

  25. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-1561.

  26. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.

  27. Jacobs TP, Siris ES, Bilezikian JP, Bauiran DC, Shane E, Canfield RE. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med 1981;94:312-316.

  28. Shah S, Hardy J, Rees E, et al. Is there a dose-response relationship for clodronate in the treatment of tumor-induced hypercalcaemia? Br J Cancer 2002;86:1235-7.

  29. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 1982;72:221-226.

  30. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134-142.

  31. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 1980;93:269-272.

  32. Watson L, Moxham J, Fraser P. Hydrocortisone suppression test and discriminant analysis in differential diagnosis of hypercalcaemia. Lancet 1980;1:1320-1325.

  33. Perlia CP, Gubisch NJ, Wolter J, EdelbergD, Dederick MM, Taylor SG III. Mithramycin treatment of hypercalcemia. Cancer 1970;25:389-394.

  34. Leyland-Jones B. Treatment of cancer related hypercalcemia: the role of gallium nitrate. Semin Oncol 2003;30:Suppl 5:13-19.

  35. Cardella CJ, Birkin BL, Rapoport A. Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. Clin Nephrol 1979;12:285-290.

  36. Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996;72:424-428.

  37. Zapf J. IGFs: function and clinical importance 3 Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. J Intern Med 1993; 234:543-552.

  38. Geenber G, Pomeranz I, Shapiro-Feinberg M,Zissin R. Fasting hypoglycemia in solitary fibrous tumor of the peritoneum: a diagnostic clue for an emergent situation. Emerg Radiol 2003;10:158-159.

  39. Nadler WA & Wolfer JH. Hepatogenic hypoglycemia associated with primary liver cell carcinoma. Archives of Internal Medicine 1929;44:700-705.

  40. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, et al. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. New England Journal of Medicine 1988;319:1434-1440.

  41. Pollak MN, Schernhammer ES & Hankinson SE. Insulinlike growth factors and neoplasia. Nature Reviews. Cancer 2004;4:505-518.

  42. Perreault L. Cushing’s syndrome from thymic neuroendocrine carcinoma: Case report and literature review. Endocrinologist 2002;12: 285-288.

  43. Shockback D, Funk J. Humoral manifestations of malignancy. En: Greenspan FS y Gardner DG Editores. Basic and Clinical Endocrinology. New York: Lange Medical Books/Mc Graw-Hill, 1997;778-791.

  44. Pallardo LF, Sáchez F, Fernandez A, Gonzalez P, Cuevas J, Saez I, y col. Carcinoma suprarrenal productor de ACTH. Rev Clin Esp 1981;162:189-192.

  45. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998;19:647-672.

  46. Findling JW, Doppman JL. Biochemical and radiologic diagnosis of Cushing’s syndrome. Endocrinol Metab Clin North Am 1994;23:511-537.

  47. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-5602.

  48. Nieman LK. Medical therapy of Cushing’s disease. Pituitary 2002;5:77-82.

  49. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006;355: 2558-2573.

  50. Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med 2000;342:1871-1876.

  51. Melmed S, Ezrin C, Kovacs K et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 1985;312:9-17.

  52. Boix E, Picó A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxford) 2002;57:131-134.




2020     |     www.medigraphic.com